Acurx director granted 2,150 stock options

Acurx Pharmaceuticals, Inc. director Thomas L. Harrison received a stock option award as compensation for service on the company’s board of directors.

Rhea-AI Filing Summary

Acurx Pharmaceuticals, Inc. director Thomas L. Harrison received a stock option award as compensation for service on the company’s board of directors. The grant covers 2,150 stock options for common stock at an exercise price of $2.36 per share.

The options were awarded at no upfront cost and will vest on April 20, 2027, meaning they become exercisable on that date. The options are scheduled to expire on April 20, 2036 if not exercised. Following this grant, Harrison holds stock options covering 2,150 shares directly.

Insider Trade Summary

Grant/Award: 2,150 shares

Grant/Award 1 txn

Insider HARRISON THOMAS L

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option	2,150	$0.00	$0.00

Holdings After Transaction: Stock Option — 2,150 contracts (Direct)

Footnotes (1)

1. F1. This stock option award is related to service on the Issuer's board of directors granted pursuant to the Issuer's Director Compensation Policy. The shares subject to the options shall vest on April 20, 2027.

Key Figures

Stock options granted: 2,150 options Exercise price: $2.36 per share Total options after grant: 2,150 options +3 more

6 metrics

Stock options granted 2,150 options Grant to director Thomas L. Harrison

Exercise price $2.36 per share Strike price for granted options

Total options after grant 2,150 options Holdings following transaction

Vesting date April 20, 2027 Date options become exercisable

Expiration date April 20, 2036 Options expire if unexercised

Underlying shares 2,150 shares Common stock underlying the options

Key Terms

Stock Option, Director Compensation Policy, exercise price, vest, +1 more

5 terms

Stock Option financial

"security_title: "Stock Option""

A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.

Director Compensation Policy financial

"granted pursuant to the Issuer's Director Compensation Policy"

exercise price financial

"conversion_or_exercise_price: "2.3600""

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vest financial

"The shares subject to the options shall vest on April 20, 2027."

A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.

expiration date financial

"expiration_date: "2036-04-20T00:00:00.000Z""

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Acurx Pharmaceuticals (ACXP) report in this Form 4 filing?

Acurx Pharmaceuticals reported that director Thomas L. Harrison received a grant of 2,150 stock options as board compensation. These options relate to common stock and were granted at an exercise price of $2.36 per share, with no cash paid at grant.

How many Acurx Pharmaceuticals (ACXP) options were granted to Thomas L. Harrison?

Thomas L. Harrison was granted 2,150 stock options in this filing. Each option is tied to one share of Acurx Pharmaceuticals common stock, providing potential future equity exposure if exercised once the options vest and before they expire.

What is the exercise price of the new ACXP stock options?

The exercise price of the new Acurx Pharmaceuticals stock options is $2.36 per share. This is the price Harrison must pay per share to convert the options into common stock once they vest, assuming he chooses to exercise them before expiration.

When do Thomas L. Harrison’s ACXP stock options vest and expire?

The stock options granted to Thomas L. Harrison vest on April 20, 2027. After vesting, they remain exercisable until their expiration on April 20, 2036, giving a long window to decide whether and when to exercise the options.

Why did Acurx Pharmaceuticals (ACXP) grant these stock options?

The options were granted as compensation for Harrison’s service on Acurx Pharmaceuticals’ board of directors under the company’s Director Compensation Policy. This aligns director incentives with shareholder interests by tying part of his compensation to the company’s stock performance.

How many ACXP options does Thomas L. Harrison hold after this grant?

Following this grant, Thomas L. Harrison holds stock options covering 2,150 shares of Acurx Pharmaceuticals common stock. This figure reflects his direct derivative holdings reported in the filing after the award was made on April 20, 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 04/22/2026 - 04:19 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

HARRISON THOMAS L

(Last) (First) (Middle)

C/O ACURX PHARMACEUTICALS, INC.,

259 LIBERTY AVENUE

(Street)

STATEN ISLAND NEW YORK 10305

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Acurx Pharmaceuticals, Inc. [ ACXP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/20/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option	$2.36	04/20/2026		A		2,150(1)		04/20/2027	04/20/2036	Common Stock	2,150	$0	2,150	D

Explanation of Responses:

1. This stock option award is related to service on the Issuer's board of directors granted pursuant to the Issuer's Director Compensation Policy. The shares subject to the options shall vest on April 20, 2027.

	/s/ Kostantinos Skordalos, Power of Attorney For: Thomas L. Harrison	04/22/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)